Status:
COMPLETED
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
Lead Sponsor:
Pfizer
Conditions:
SARS-CoV-2 Infection
Eligibility:
All Genders
12+ years
Brief Summary
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19. This study is intended to be...
Detailed Description
This is a multicenter cohort study to be conducted in individuals with SARS-CoV-2 infection who are treated with this product, and the investigator will enter the information required in this study in...
Eligibility Criteria
Inclusion
- Subjects who are administered PAXLOVID PACK and have no history of using this drug.
Exclusion
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
March 31 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 10 2023
Estimated Enrollment :
3346 Patients enrolled
Trial Details
Trial ID
NCT05263908
Start Date
March 31 2022
End Date
July 10 2023
Last Update
September 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Local County
Tokyo, Japan, 1518589